PharmaTimes https://pharmatimes.com in-depth news, features and insights for the pharmaceutical and healthcare sectors Thu, 09 Jul 2026 09:53:01 +0000 en-US hourly 1 https://pharmatimes.com/wp-content/uploads/2023/11/PT-icon-150x150.png PharmaTimes https://pharmatimes.com 32 32 232894315 Pluripotent stem cell trial for Huntington’s disease https://pharmatimes.com/news/pluripotent-stem-cell-trial-for-huntingtons-disease/ Thu, 09 Jul 2026 09:52:31 +0000 https://pharmatimes.com/?p=104792 Early-stage study marks milestone for regenerative medicine

]]> 104792 Jascayd gains UK licence for treatment of pulmonary fibrosis https://pharmatimes.com/news/jascayd-gains-uk-licence-for-treatment-of-pulmonary-fibrosis/ Thu, 09 Jul 2026 09:43:51 +0000 https://pharmatimes.com/?p=104788 New option for adults with IPF and PPF

]]> 104788 Grünenthal receives FDA designations for tegacorat in Duchenne muscular dystrophy https://pharmatimes.com/news/grunenthal-receives-fda-designations-for-tegacorat-in-duchenne-muscular-dystrophy/ Wed, 08 Jul 2026 09:24:37 +0000 https://pharmatimes.com/?p=104785 SEGRAM aims to offer an alternative to glucocorticoid‑based treatment

]]> 104785 The overlooked burden of ageing https://pharmatimes.com/thought_leadership/the-overlooked-burden-of-ageing/ Wed, 08 Jul 2026 09:11:41 +0000 https://pharmatimes.com/?p=104780 Why the UK needs a unified strategy for chronic disease and adult vaccination

]]> 104780 Compass Pathways reports six‑month data confirming durable profile of COMP360 https://pharmatimes.com/news/compass-pathways-reports-six-month-data-confirming-durable-profile-of-comp360/ Tue, 07 Jul 2026 13:09:22 +0000 https://pharmatimes.com/?p=104774 Second phase 3 trial shows sustained benefit and supports forthcoming regulatory submission

]]> 104774 Ferrer and Prilenia begin confirmatory study of pridopidine in Huntington’s disease https://pharmatimes.com/news/ferrer-and-prilenia-begin-confirmatory-study-of-pridopidine-in-huntingtons-disease/ Tue, 07 Jul 2026 12:54:35 +0000 https://pharmatimes.com/?p=104772 New phase 3 trial to assess impact on disease progression, function and quality of life

]]> 104772 Wegovy pill launches in UK as first daily oral GLP‑1 for weight management https://pharmatimes.com/news/wegovy-pill-launches-in-uk-as-first-daily-oral-glp-1-for-weight-management/ Mon, 06 Jul 2026 10:20:03 +0000 https://pharmatimes.com/?p=104767 Option offers once‑daily semaglutide tablets for adults living with obesity

]]> 104767 Sofinnova reports Myricx Bio to be acquired by Novartis https://pharmatimes.com/news/sofinnova-reports-myricx-bio-to-be-acquired-by-novartis/ Mon, 06 Jul 2026 10:09:52 +0000 https://pharmatimes.com/?p=104765 Deal brings together Novartis oncology capabilities with Myricx Bio’s next‑gen ADC platform

]]> 104765 Francis Crick Institute and Medicines Discovery Catapult open applications for next KQ Labs cohort https://pharmatimes.com/news/francis-crick-institute-and-medicines-discovery-catapult-open-applications-for-next-kq-labs-cohort/ Thu, 02 Jul 2026 13:40:35 +0000 https://pharmatimes.com/?p=104763 Accelerator seeks early‑stage data‑driven health ventures for five‑month programme

]]> 104763 Novartis receives European Commission approval for Itvisma for spinal muscular atrophy https://pharmatimes.com/news/novartis-receives-european-commission-approval-for-itvisma-for-spinal-muscular-atrophy/ Thu, 02 Jul 2026 13:32:11 +0000 https://pharmatimes.com/?p=104760 EC backs first gene replacement therapy for broad sma population

]]> 104760